Citations

Showing 10 of 108119 citations.

The Global Reading Room: Nuclear Medicine Imaging of a Diabetic Foot Ulcer
Israel, Ora , Nakajo, Masatoyo , Nunes, Rafael Fernandes , Packard, Annie T.

Mayo Clinic

American Journal of Roentgenology | January 5, 2022 | Volume: 219 | Issue: 4 | Pages: 681-682

10.2214/ajr.21.27251 | PMID 34985310 Get It

Association of Cirrhosis and Other Patient and Procedural Characteristics With Postembolization Syndrome After Bland Hepatic Artery Embolization for Hepatic Malignancy
Rmilah, Anan Abu , Qrareya, Mohammad N., Fleming, Chad J. , Alkurashi, Adham K. , Nyberg, Scott L. , Leise, Michael D. , Andrews, James C. , Fleming, Chad, Nyberg, Scott, Leise, Michael, Qrareya, Mohammad N.

Mayo Clinic

American Journal of Roentgenology | January 5, 2022 | Volume: 218 | Issue: 6 | Pages: 1030-1039

10.2214/ajr.21.26806 | PMID 34985314 Get It

Masking for School-Age Children With Epilepsy: We Do Have Consensus!
Fine, Anthony L. , Nickels, Katherine , Wong-Kisiel, Lily C. , Fine, Anthony , Nickels, Katherine C , Wong‐Kisiel, Lily C. , Wirrell, Elaine

Mayo Clinic

Journal of Child Neurology | January 5, 2022 | Volume: 37 | Issue: 2 | Pages: 127-132

10.1177/08830738211063684 | PMID 34986033 Get It

Introduction This study was designed to assess current recommendations from child neurologists and epileptologists on masking for school-age children with epilepsy. Methods A 7-item survey was created and sent out to members of the Child Neurology Society and Pediatric Epilepsy Research Consortium in August of 2021 to assess current practice and provider recommendations on masking. Results One hundred four individuals participated with representation from all regions of the United States. Masking was recommended by 95.1%, with 63.4% (n = 66) noting exception of those with severe intellectual disability, autism, and behavioral problems. Of those who write exemption letters, 54% write these <5% of the time. Only 3% reported potential adverse events associated with masking. Conclusion Nearly all respondents recommended masking for school-age children with epilepsy. Potential risks of masking and adverse events were low. Improved guidance on masking is needed to ensure academic success of our patients with epilepsy.
Effects of Reversal Technique for Neuromuscular Paralysis on Time to Recovery of Bowel Function after Craniotomy
Deljou, Atousa , Soleimani, Jalal , Schroeder, Darrell R. , Schroeder, Darrell , Šprung, Juraj , Weingarten, Toby N.

Mayo Clinic

The American Surgeon™ | January 5, 2022 | Volume: 89 | Issue: 5 | Pages: 1605-1609

10.1177/00031348211058631 | PMID 34986061 Get It

Background Non-depolarizing neuromuscular blockade can be reversed with neostigmine/glycopyrrolate or sugammadex. We test the hypothesis that sugammadex is associated with earlier postoperative recovery of bowel function (first bowel movement, BM). Methods In adult patients undergoing craniotomy from 2016 to 2019, we identified time of first postoperative BM after receiving neostigmine/glycopyrrolate or sugammadex to reverse neuromuscular blockade. Logistic and proportional hazard regression, with and without inverse probability of treatment weighting (IPTW), were used to assess whether sugammadex is associated with earlier recovery of bowel function. Results Seven hundred and thirty-one patients underwent craniotomy, 323 (44.2%) received neostigmine/glycopyrrolate, and 408 (55.8%) sugammadex. From logistic regression analysis, the proportion of patients having a BM within the first 24 and 48 hours was higher in sugammadex group (unadjusted OR [95% CI]) 1.79 [1.16 to 2.77] P = .009; and 1.45 [1.08 to 1.94] P = .014; IPTW adjusted OR [95% CI]) 1.58 [.95, 2.61] P = .078; and 1.38 [.95 to 2.02] P = .095 for 24 and 48 h, respectively). From proportional hazards regression, sugammadex was associated with improved bowel function recovery (unadjusted hazard ratio (HR) [95% CI] 1.35 [1.08, 1.68], P = .008; IPTW adjusted HR 1.29 [.97 to 1.71], P = .076). Conclusion Patients undergoing craniotomy who had neuromuscular blockade reversed with sugammadex may have earlier recovered bowel function compared to patients reversed with neostigmine/glycopyrrolate.
Hereditary myopathies associated with hematological abnormalities
Beecher, Grayson , Liewluck, Teerin , Liewluck, T , Beecher, Grayson , Fleming, Mark D.

Mayo Clinic

Muscle & Nerve | January 5, 2022 | Volume: 65 | Issue: 4 | Pages: 374-390

10.1002/mus.27474 | PMID 34985130 Get It

AbstractThe diagnostic evaluation of a patient with suspected hereditary muscle disease can be challenging. Clinicians rely largely on clinical history and examination features, with additional serological, electrodiagnostic, radiologic, histopathologic, and genetic investigations assisting in definitive diagnosis. Hematological testing is inexpensive and widely available, but frequently overlooked in the hereditary myopathy evaluation. Hematological abnormalities are infrequently encountered in this setting; however, their presence provides a valuable clue, helps refine the differential diagnosis, tailors further investigation, and assists interpretation of variants of uncertain significance. A diverse spectrum of hematological abnormalities is associated with hereditary myopathies, including anemias, leukocyte abnormalities, and thrombocytopenia. Recurrent rhabdomyolysis in certain glycolytic enzymopathies co‐occurs with hemolytic anemia, often chronic and mild in phosphofructokinase and phosphoglycerate kinase deficiencies, or acute and fever‐associated in aldolase‐A and triosephosphate isomerase deficiency. Sideroblastic anemia, commonly severe, accompanies congenital‐to‐childhood onset mitochondrial myopathies including Pearson marrow‐pancreas syndrome and mitochondrial myopathy, lactic acidosis, and sideroblastic anemia phenotypes. Congenital megaloblastic macrocytic anemia and mitochondrial dysfunction characterize SFXN4‐related myopathy. Neutropenia, chronic or cyclical, with recurrent infections, infantile‐to‐childhood onset skeletal myopathy and cardiomyopathy are typical of Barth syndrome, while chronic neutropenia without infection occurs rarely in DNM2‐centronuclear myopathy. Peripheral eosinophilia may accompany eosinophilic inflammation in recessive calpainopathy. Lipid accumulation in leukocytes on peripheral blood smear (Jordans' anomaly) is pathognomonic for neutral lipid storage diseases. Mild thrombocytopenia occurs in autosomal dominant, childhood‐onset STIM1 tubular aggregate myopathy, STIM1 and ORAI1 deficiency syndromes, and GNE myopathy. Herein, we review these hereditary myopathies in which hematological features play a prominent role.
Metabolic associated fatty liver disease and acute-on-chronic liver failure: common themes for common problems
Córdova-Gallardo, Jacqueline, Keaveny, Andrew P., Qi, Xingshun, Méndez-Sánchez, Nahum, Cordova-Gallardo, Jacqueline , Keaveny, Andrew P., Qi, Xingshun, Méndez-Sánchez, Nahum

Mayo Clinic

European Journal of Gastroenterology & Hepatology | January 5, 2022 | Volume: 33 | Issue: 1S | Pages: e84-e93

10.1097/meg.0000000000002335 | PMID 34985050 Get It

Metabolic associated fatty liver disease (MAFLD) affects 20–30% of the worldwide population and is becoming the most common cause of chronic liver disease, cirrhosis and hepatocellular carcinoma (HCC). MAFLD is the hepatic expression of metabolic dysfunction correlated with a variety of metabolic comorbidities including obesity, dyslipidemia, hypertension and type 2 diabetes (T2DM). Obesity, altered gut permeability, chronic inflammation and dysbiosis related to MAFLD might predispose patients with cirrhosis to the development of acute-on-chronic liver failure (ACLF); however, this relationship remains unclear. ACLF is a syndrome with high short-term mortality, presenting with acute hepatic decompensation associated with organ failures in patients with underlying chronic liver disease with or without an identifiable precipitating event. While this syndrome can occur in any patient with cirrhosis, the increasing prevalence of cirrhosis due to MAFLD is of great concern because, in a recent analysis, MAFLD was the fastest rising cause of cirrhosis associated with ACLF among patients listed for LT in the US. In this review, we will discuss the current knowledge on MAFLD and the development of ACLF.
Airway Amyloidosis
Baqir, Misbah , Schwegman, Alex, Maldonado, Fabien , Johnson, Tucker F. , Ryu, Jay H. , Ryu, Jay H

Mayo Clinic

Journal of Bronchology & Interventional Pulmonology | January 5, 2022 | Volume: 29 | Issue: 4 | Pages: 275-282

10.1097/lbr.0000000000000836 | PMID 34984992 Get It

Background: Amyloidosis can involve any compartment in the thorax. We aimed to explore the clinical and radiologic presentation, treatment, and clinical course of airway amyloidosis. Methods: A computer-assisted search was performed to identify patients who had biopsy-proven airway amyloidosis and were evaluated at Mayo Clinic in Rochester, MN, from January 1, 1997 through December 31, 2019. Demographic, clinical, and radiologic features along with clinical outcomes were analyzed. Results: We identified 43 patients who had airway amyloidosis. Median age was 60 years (range: 33 to 91 y), and 58% were female. Shortness of breath (63% of patients) and cough (44%) were the most common presenting symptoms. Most patients (82%) had localized amyloidosis with light chain being the most common amyloid type; 63% had tracheobronchial amyloidosis, and 23% had tracheal and upper airway involvement. On computed tomography of the chest, the most common findings were airway wall thickening with nodularity (60% of patients), airway calcification (53%), and airway occlusion without collapse (47%). On bronchoscopy (33 patients), the extent of amyloid involvement was most commonly submucosal (n=15) or nodular (n=8). External beam radiotherapy was the most common treatment modality. Among the 30 patients who had follow-up at our institution, the prognosis appeared to depend on the extent of the disease and whether patients had localized or systemic amyloidosis. Conclusion: Computed tomography of the chest, bronchoscopy, and biopsy are needed to establish the diagnosis of airway amyloidosis, and systemic amyloidosis should be ruled out. Treatment of amyloidosis requires a multidisciplinary approach.
Delayed systemic urticarial reactions following mRNA COVID-19 vaccination
Pitlick, Mitchell M. , Joshi, Avni Y. , Gonzalez‐Estrada, Alexei , Chiarella, Sergio E.

Mayo Clinic

Allergy and Asthma Proceedings | January 5, 2022 | Volume: 43 | Issue: 1 | Pages: 40-43

10.2500/aap.2022.43.210101 | PMID 34983709 Get It

Background:As the vaccination campaign in response to the coronavirus disease 2019 (COVID-19) pandemic continues, concerns with regard to adverse reactions to the vaccine remain. Although immediate hypersensitivity reactions have received much attention, delayed systemic urticarial reactions after vaccination can occur.Objective:To describe the clinical presentation, vaccine excipient skin testing results, and outcomes of subsequent COVID-19 vaccination in patients who experienced delayed systemic urticarial reactions after messenger RNA (mRNA) COVID-19 vaccination.Methods:This was a retrospective case series of 12 patients referred to the Mayo Clinics in Rochester, Minnesota, and Jacksonville, Florida, between January 19, 2021, and April 30, 2021, for evaluation of delayed systemic urticarial reactions after mRNA COVID-19 vaccination. Demographics, medical and allergic history, reaction details, vaccine excipient skin testing results (when performed), and the outcome after subsequent vaccination were collected for each patient.Results:The mean age of the patients was 52 years, all were white, and 9 (75%) were women. Half of the patients had a history of drug allergy, and one had a history of chronic spontaneous urticaria. Seven patients reacted to the Pfizer-BioNTech vaccine and five reacted to the Moderna vaccine. Seven patients developed symptoms between 8 and 24 hours after vaccination. Nine patients required antihistamines for treatment. The median time to symptom resolution was 4 days. Nine patients underwent allergist-directed COVID-19 vaccine excipient skin testing, all of which were negative. Ten patients chose to receive their next mRNA COVID-19 vaccine dose, and four patients experienced recurrent delayed urticaria.Conclusion:Delayed systemic urticarial reactions after mRNA COVID-19 vaccination were not life-threatening, could be treated with antihistamines, and were not predicted with vaccine excipient skin testing. They were not a contraindication to subsequent vaccination, although patients should be counseled with regard to the possibility of recurrence.
Population-based incidence of food allergies in Olmsted County over 17 years
Almodallal, Yahya , Weaver, Amy L. , Joshi, Avni Y.

Mayo Clinic

Allergy and Asthma Proceedings | January 5, 2022 | Volume: 43 | Issue: 1 | Pages: 44-49

10.2500/aap.2022.43.210088 | PMID 34983710 Get It

Background: There is growing concern about the rising incidence and prevalence of food allergy globally. We previously reported the incidence of food allergy in Olmsted County, Minnesota, between 2002 and 2011. We sought to update the incidence and temporal trends of food allergies in our region through 2018. Methods: By using the Rochester Epidemiology Project, all Olmsted County residents, with an incident diagnosis of food allergy between January 2, 2012, and December 31, 2018, were identified and their medical records were reviewed. These cases were combined with the previously collected incidence cases from January 2, 2002, and December 31, 2011, to understand longitudinal trends in food allergy incidence rates. Results: Over the 17-year study period, 1076 patients (58.0% male patients, 72.1% white) were diagnosed with an incident food allergy. The median (interquartile range) age at first diagnosis was 2.0 years (1.1-8.4 years). The overall annual incidence rate for all ages was 3.9 (95% confidence interval [CI], 3.6‐4.1) per 10,000 person-years and was significantly higher in male than in female patients (4.4 [95% CI, 4.0‐4.7] and 3.3 [95% CI, 3.0‐3.6], respectively; p < 0.001). The most common food allergen was egg in infancy (57.7%), peanuts in ages 1‐4 years (58.3%), tree nuts in ages 5‐18 years (57.4%), and seafood in adults (≥19 years) (45.3%). Conclusion: The incidence of food allergy in Olmsted County steadily increased from 2002 to 2008, then remained relatively stable between the years 2008 and 2013, and again presented a rising trend over the next 5 years until 2018. This warrants further investigations into the effects of changes in guidelines for early introductions of allergenic foods and other factors that affect causality.
Transcatheter aortic valve replacement outcomes in solid organ transplant recipients
Campany, Megan , Bhandarkar, Archis R. , Bydon, Mohamad , Donato, Britton B. , Sell‐Dottin, Kristen , Campany, Megan E , Sell-Dottin, Kristen A

Mayo Clinic

Journal of Cardiac Surgery | January 5, 2022 | Volume: 37 | Issue: 3 | Pages: 602-607

10.1111/jocs.16202 | PMID 34985156 Get It